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Abstract
Objective
To identify adverse events (AEs) associated with Levetiracetam (LEV) in children.
Methods
Databases EMBASE (1974-February 2015) and Medline (1946-February 2015) were
searched for articles in which paediatric patients (18 years) received LEV treatment for
epilepsy. All studies with reports on safety were included. Studies involving adults, mixed
age population (i.e. children and adults) in which the paediatric subpopulation was not suffi-
ciently described, were excluded. A meta-analysis of the RCTs was carried out and associ-
ation between the commonly reported AEs or treatment discontinuation and the type of
regimen (polytherapy or monotherapy) was determined using Chi2 analysis.
Results
Sixty seven articles involving 3,174 paediatric patients were identified. A total of 1,913 AEs
were reported across studies. The most common AEs were behavioural problems and som-
nolence, which accounted for 10.9% and 8.4% of all AEs in prospective studies. 21 pro-
spective studies involving 1120 children stated the number of children experiencing AEs.
47% of these children experienced AEs. Significantly more children experienced AEs with
polytherapy (64%) than monotherapy (22%) (p<0.001). Levetiracetam was discontinued in
4.5% of all children on polytherapy and 0.9% on monotherapy (p<0.001), the majority were
due to behavioural problems.
Conclusion
Behavioural problems and somnolence were the most prevalent adverse events to LEV
and the most common causes of treatment discontinuation. Children on polytherapy have a
greater risk of adverse events than those receiving monotherapy.
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Introduction
Levetiracetam (LEV) is one of the most commonly prescribed new generation antiepileptic
drugs (AEDs). It accounts for about 8% of paediatric AED prescriptions in the UK [1] and 7%
in Germany [2] and Hong Kong [3]. It was approved for adult use in Europe in 2000 and sub-
sequently for paediatric use in 2005[4]. In the UK, it is recommended as an adjunctive agent
for partial seizures, myoclonic seizures as well as for some epilepsy syndromes such as: rolandic
epilepsy and late-onset childhood occipital epilepsy [5]. Some of the adverse reactions com-
monly associated with LEV include: somnolence, dizziness and behavioural problems. Beha-
vioural problems are more commonly reported in children than adults [6].
LEV undergoes elimination predominantly by renal excretion. Metabolism by hydrolysis
and hydroxylation is a minor process. This is thought to reduce the risk of drug-drug interac-
tions [7]. Its onset of action is rapid, which makes it a candidate drug for the treatment of status
epilepticus [8].Levetiracetam is approved for use in children as adjunctive therapy. It can be
prescribed as monotherapy to adolescents 16 years old and over. Although, the safety of the
drug in children and adolescents less than 16 years old is unknown, monotherapy use in this
population is quite common [6].
Due to the increasing utilisation of LEV in children, this systematic review aims to evaluate
the available evidence, from all studies, on the safety of LEV in children.
Method
This review was carried out as per PRISMA guidelines. The systematic review protocol was not
published
Search strategy
Databases EMBASE (1974- February 2015) and Medline (1946-February 2015) were searched
for articles in which paediatric patients (18 years) received LEV treatment for epilepsy. The
paediatric search terms used were: paediatric or pediatric or boy or girl or pediatric or
child or neonat or infan or adolescen or newborn or baby or toddler or young, in title [9].
This was combined with levetiracetam, also in title. Output was limited to humans and journal
articles. Only studies that evaluated and reported safety outcomes were included. Papers pub-
lished in English, Chinese, French and Spanish were included. Studies involving adults, mixed
age population (i.e. children and adults) in which the paediatric subpopulation was not suffi-
ciently described, were excluded.
Data extraction
The types and number of AEs were extracted. Other extracted data included: the age of the
patients, the dose, route of administration, the number of study participants, co-administered
drugs, type of regimen (monotherapy or polytherapy) and the duration of follow up. Adverse
reactions resulting in the discontinuation of LEV treatment were also documented
Data quality assessment
The quality of the RCTs were assessed using the Cochrane collaboration’s tool for assessing
risk of bias in randomised trials [10]. The quality of the prospective observational studies were
assessed using the System for the Unified Management of the Review and Assessment of Infor-
mation (SUMARI)[11]. Data from any study fulfilling 4 or more of the 9 criteria were included
in the final data aggregation (S1 appendix). All studies were independently assessed by two
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reviewers. Any conflicting outcomes were discussed between the reviewers before a verdict was
agreed upon.
Data collection and statistical analysis
Ameta-analysis of the RCTs was done using Revman version 6. Only AEs identified from 2 or
more studies were analysed. The relative risks of AEs present in at least two RCTs were calcu-
lated, with a RR>1 suggesting that more AE were associated with LEV treatment. The data
were considered homogeneous I250% or Chi2 p0.05. Homogeneous data were analysed
using the fixed effect model while the random effect model was used for heterogeneous data.
Risk of AEs per 100 patient was also determined in both prospective and retrospective studies.
Chi2 analysis of the association between each AE and the treatment regimen (polytherapy or
monotherapy) was performed. Chi2 analysis of the association between treatment discontinua-
tion and the treatment regimen was also conducted. P-values<0.05 were considered statisti-
cally significant for all analyses.
Results
Description of study characteristics
Sixty seven articles involving 3,174 paediatric patients were identified (Fig 1). No RCT or pro-
spective cohort study was excluded after quality analysis (Fig 2). Quality analysis was not per-
formed for retrospective studies. A total of 1,913 AEs were reported across studies. The largest
numbers of children (1,461) were recruited within the 21 retrospective studies (Table 1). The
greatest number of AEs (897) however was reported in the 20 prospective cohort studies. There
were 6 RCTs with 415 reports of AEs.
The median period of follow-up was 24 weeks [IQR: 16.5–51 weeks]. Levetiracetam was
administered orally in the majority of the studies (32 studies). In 8 studies, it was given intrave-
nously; while both IV and oral LEV were administered in one study. Another study used a
combination of IV, oral, rectal and nasogastric tube administration. The route of administra-
tion was not indicated in 8 studies. In 22 studies, LEV was given as an adjunct to other AEDs;
while it was administered alone in 19 of the studies. Combinations of monotherapy and poly-
therapy regimen were given in 10 studies.
Levetiracetam dosing
Levetiracetam dose was titrated in all studies. The median initial dose was 10mg/kg/day [IQR:
10–14]; while the median final dose was 60mg/kg/day [IQR: 40–60]. There was no significant
difference (p = 0.986) between the median initial dose in polytherapy (10mg/kg/day [IQR: 10–
20]) and monotherapy studies (10mg/kg/day [IQR: 10–10.5]). The median final dose in poly-
therapy studies (60mg/kg/day [IQR: 60–61.5]) was however significantly higher (p = 0.003)
than in monotherapy studies (30mg/kg/day [IQR: 35–52.5]).
Evidence from Randomised controlled trials
Six RCTs were identified, 4 of which were placebo controlled trials (Table 2). Three of the 6
studies were monotherapy studies comparing LEV treatment with sulthiame (STM), oxcarba-
zepine (OXC) and placebo respectively. In one study, airway problems (AEs not specified)
were significantly more with STM than LEV [12]. None of the other studies reported any sig-
nificant difference in AEs.
The three polytherapy studies were add-on placebo controlled studies. Although there was a
twofold increase in risk of abnormal behaviour in LEV treated children versus placebo [RR:
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1.92 95%CI: 1.01–3.63], this did not reach statistical significance (p = 0.05). Twelve percent of
children on LEV developed abnormal behaviours such as: aggression, irritability and hyperac-
tivity; compared to 6% of those on placebo. There was also an increase in the risk of
Fig 1. Flow chart of included studies.
doi:10.1371/journal.pone.0149686.g001
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somnolence in LEV treated children compared with placebo [RR: 2.24, 95%CI: 1.29–3.86,
p = 0.004], about 18% vs. 8% respectively. About 8.5% of LEV treated children had reports of
anxiety compared with 1.5% of placebo, representing a significant increase [RR: 4.81, 95%CI:
Fig 2. Risk of bias summary and graph.
doi:10.1371/journal.pone.0149686.g002
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1.27–18.20, p = 0.02] (Fig 3). There was no significant difference in the risks of other com-
monly reported AEs such as loss of appetite, vomiting, dizziness, rash and insomnia (Fig 3).
Evidence from prospective studies
Prospective studies included prospective cohort studies, RCTs and PK studies and included
1690 children (Tables 2 and 3). 21 of the 30 studies stated the number of children who experi-
enced AEs and included 1120 children. A total of 995 AEs were reported in 525 children
(47%). The majority (26%) of the AEs were psychiatric events. Behavioural problems
accounted for 64% of all psychiatric events. 10.9% of all AEs were behavioural problems. Com-
mon ones included: aggression, irritability and hyperactivity. In several studies, the form of the
behavioural problem was not reported. Neurological AEs were also frequently reported,
accounting for 24% of AEs. Somnolence was the most common neurological AE (Table 4)
occurring in 8.4% of children. Common (1/100 to<1/10) neurological events included:
headache, dizziness and drowsiness. Vomiting, abdominal pain and diarrhoea were the com-
monly reported gastrointestinal events. 12% of AEs were gastrointestinal (Table C in S1 Table).
There were 7 prospective studies involving 229 paediatric patients where it was possible to
determine the number of children with AEs following LEV monotherapy. Fifty one (22%) of
these children had at least one AE. There were 10 prospective studies involving 613 paediatric
patients on polytherapy and 392 children (64%) had at least one AE. Polytherapy was associ-
ated with a significantly higher rate of AEs (p<0.001). There were 82 children who experienced
AEs where it was not possible to determine whether they were on polytherapy or monotherapy.
Table 1. Summary of included studies.
Study type Number of studies Number of AEs (%) Number of patients (%)
RCTs 6 415 306 (10%)
Prospective cohort studies 20 897 1311 (41%)
Pharmacokinetic studies 4 32 73 (2%)
Retrospective cohort studies 21 546 1461 (46%)
Case reports 16 23 23 (1%)
Total 67 1913 3174
doi:10.1371/journal.pone.0149686.t001
Table 2. Data summary for Randomised controlled trials.
Reference No receiving
LEV
Comparator Age
(yrs)
Initial dose
(mg/kg/day)
Final dose [mean]
(mg/kg/d)
Route Regimen No of
AEs
Follow-up
(wks)
Borgraeffe et al,
2013[12]
22 Sulthiame 6–12 10 30 Oral Monotherapy 64* 24
Fattore et al, 2011
[13]
38 Placebo 4–15 10 30[28.5] Oral Monotherapy 3 3
Levisohn et al,
2009[14]
64 Placebo NA 20 60[53.6] Oral Polytherapy 145 23
Pina Garza et al,
2009[15]
60 Placebo <4 20–25 40–50[45.5] Oral Polytherapy 26 3
Glauser et al, 2006
[16]
101 Placebo 4–16 20 60 Oral Polytherapy 174 22
Coppola et al,
2006[17]
21 OXC 3–14 5 30 Oral Monotherapy 3 NA
OXC-oxcarbazepine
* Number of children with AEs not stated.
doi:10.1371/journal.pone.0149686.t002
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Fig 3. Relative risks of AEs of LEV and placebo.
doi:10.1371/journal.pone.0149686.g003
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The risks of headache, vomiting, hyperactivity and aggression were all lower among monother-
apy users (p<0.001). The only AE significantly more common in association with monother-
apy was irritability and there was no difference in the occurrence of somnolence between
polytherapy and monotherapy users (Table 5).
Evidence from retrospective studies
There were 21 retrospective studies (Table A in S1 Table). Similar to reports from prospective
studies, both somnolence and abnormal behaviour were the most commonly reported AEs.
The majority of the 546 AEs in these studies were psychiatric events (46%). Seventy eight per-
cent of psychiatric events were behavioural problems. The types of behavioural problems were
not specified in many of the studies; however, the commonly reported behavioural problems
were aggression (3.8/100) and irritability (1.6/100). Neurological events were also frequently
reported (34%); while only 3% of AEs were gastrointestinal events (Table B in S1 Table).
Case reports
There were 16 case reports, with 23 reports of adverse drug reactions (ADRs). The majority of
the reported cases were aggravated seizures and psychoses. Other reports included rash, weight
Table 3. Prospective cohort studies.
Author (year) No
participants
Age
(yrs)
Initial dose (mg/
kg/day)
Final dose [mean]
(mg/kg/d)
Route Regimen No of
AEs
Follow-up
(weeks)
Callenbach et al, 2007
[18]
33 4–16 10 60 [22]† Oral Polytherapy 139 26
Nakken et al, 2003([19] 44 1–17 10 40 Oral Polytherapy 11* 32
Kanemura et al, 2013
[20]
61 1.3–18 10 60[46.1] Oral Polytherapy 2 24
Chhun et al, 2011[21] 102 NA 10 60[31.1] Oral Polytherapy 97 24
Kim et al, 2014[22] 55 1.1–18.6 10 20–80[41.9] Oral Polytherapy 21 16
Glauser et al, 2002[23] 24 6–12 10 40[36.3] Oral Polytherapy 70* 18
Zhang et al, 2014 [24] 105 NA 20 30–40 NA Polytherapy 2* NA
Schieman et al, 2012[25] 103 4–16 10 100[50.2] NA Polytherapy 196 48
McTague et al, 2012[26] 51 0.3–18 5–30 [14.4] IV Monotherapy 3 NA
Weinstock et al, 2013
[27]
62 0.1–16 14->40 NA IV Monotherapy 32 3
Furwensteches et al,
2010[28]
6 <28days 10 50 Oral Monotherapy 1 90
Feng et al, 2014[29] 210 1–18 10 60 Oral Monotherapy 171* 208
Verrotti et al, 2007[30] 21 5–12 NA NA Oral Monotherapy 2 52
Verrotti et al, 2009[31] 12 6–16 10 20.7–45.2 Oral Monotherapy 4 72
Gao et al, 2008[32] 32 0.7–12 10 40[35] NA Monotherapy 11* NA
Lagae et al, 2005[33] 77 0.5–16 12 62[33]† Oral Mixed 12* 20
Dureau et al, 2014[34] 116 <16 NA NA Oral Mixed 15 52
Ng et al, 2010[35] 30 0.5–15 NA 31.1–50.3 IV/
Oral
Mixed 11 4
Ramatani et al, 2010[36] 38 <28days 10 45–60 IV Mixed 2* 52
Li et al, 2011[37] 129 0–16 10 60[29]† NA Mixed 97 52
* Number of children with AEs not stated
†median.
doi:10.1371/journal.pone.0149686.t003
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loss, depression, autistic regression, acute pancreatitis, elevated alkaline phosphatase, thrombo-
cytopaenia, interstitial nephritis and interstitial lung disease (Table D in S1 Table). The single
report of drug interaction was a case of renal failure in a 15 year old boy who received metho-
trexate for acute lymphoblastic leukaemia [38].
Treatment discontinuation due to adverse drug reactions
There were 69 reported cases of LEV treatment discontinuation due to ADRs, from a total of
3151 children receiving LEV (2.2%). Forty five of these were from retrospective studies and 24
from prospective studies. 56 of the 1256 children on polytherapy (4.5%) and 7 of the 795
receiving monotherapy (0.9%) discontinued treatment due to toxicity. Six cases of discontinua-
tion were in studies with mixed (polytherapy and monotherapy) treatment. The discontinua-
tion rates were significantly higher on polytherapy than on monotherapy (p<0.001). The
Table 4. Risk of adverse events occurring in10 children from 30 prospective studies.
System Adverse Event Number of patients Risk per 100 patients 95% Conﬁdence Interval
Psychiatry
Behavioural Irritability 71 4.2 3.2–5.2
Abnormal behaviour 52 3.1 2.3–3.9
Hyperactivity 49 2.9 2.1–3.7
Aggression 44 2.6 1.9–3.5
Others Dysphoria 32 1.9 1.3–2.6
Cognitive problems 23 1.4 0.8–2.0
Anxiety 29 1.7 1.1–2.3
Learning problem 11 0.7 0.3–1.1
Nervous
Somnolence 142 8.4 7.1–9.7
Headache 64 3.8 2.9–4.7
Other sleep disorders 29 1.7 1.1–2.3
Dizziness 21 1.2 0.7–1.7
Aggravated seizure 16 0.9 0.5–1.4
Insomnia 14 0.8 0.4–1.2
Tremor 11 0.7 0.3–1.1
General
Loss of appetite 80 4.7 3.7–5.7
Weakness 64 3.8 2.9–4.7
Pyrexia 44 2.6 1.9–3.5
Fatigue 35 2.1 1.4–2.8
Gastro intestinal
Vomiting 50 2.9 2.1–3.7
Abdominal pain 34 2.0 1.3–2.7
Diarrhoea 28 1.7 1.1–2.3
Nausea 14 0.8 0.4–1.2
Gastroenteritis 10 0.6 0.2–1.0
Respiratory
Nasopharyngitis 41 2.4 1.7–3.1
Respiratory tract infection 36 2.1 1.4–2.8
Cough 24 1.4 0.8–2.0
Skin Rash 16 0.9 0.5–1.4
doi:10.1371/journal.pone.0149686.t004
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majority of discontinuation (33 cases, 48%) was due to behavioural problems. The nature of
the behavioural problems was not stated for 22 cases; there were 6 cases of aggression and 5 of
irritability. There were 7 cases of somnolence (10%) and 6 cases of seizure aggravation (9%)
resulting in treatment discontinuation (Table 6).
Discussion
This review shows that behavioural problems and somnolence are the most common adverse
events to LEV, with behavioural problems being the most common reasons for treatment dis-
continuation. Compared with placebo, a twofold increase in the risk of abnormal behaviour
was reported in children receiving LEV. This is in line with a previous systematic review, which
was focused on only behaviour [39]. Behavioural effects seen with LEV treatment could be pos-
itive or negative. Examples of positive effects include: increased energy, vigilance, and activity.
Aggression, irritability, hyperactivity and nervousness are frequently observed negative effects.
Overall, 2.2% of children receiving LEV had to stop taking the drug due to toxicity. This is sim-
ilar to the discontinuation rate observed with lamotrigine [40]. When used in combination
with another AED, the discontinuation rate was 4.5%.
A systematic review in adults had reported a higher prevalence of anxiety and depression
[41]. A prior history of behavioural problem, learning disability and psychiatric conditions can
predispose to behavioural decompensation in children on LEV treatment [42]. Behavioural
problems associated with LEV have been shown to be worse in epilepsy patients than those
Table 5. Comparison of the most frequent AEs (from 23 prospective studies) among children on polytherapy andmonotherapy
Adverse event Poly [n = 786] Mono[n = 493] P value
Headache 54 9 < 0.001*
Vomiting 47 3 < 0.001*
Hyperactivity 33 0 < 0.001*
Aggression 29 3 <0.001*
Pyrexia 35 6 0.001*
Nasopharyngitis 41 0 < 0.001*
Respiratory tract infection 34 0 < 0.001*
Abdominal pain 24 0 < 0.001*
Anxiety 24 0 < 0.001*
Diarrhoea 28 0 < 0.001*
Cough 24 0 < 0.001*
Cognitive problems 19 4 0.04*
Drowsiness 17 1 0.003*
Rash 15 1 0.008*
Nausea 14 0 0.001*
Irritability 26 45 < 0.001*
Somnolence 68 35 0.3
Loss of appetite 39 19 0.4
Weakness 36 33 0.1
ǂ Abnormal behaviour 100 81 0.1
Dizziness 15 3 0.1
Aggravated seizure 11 4 0.4
ǂ includes irritability, aggression, hyperactivity and unclassiﬁed abnormal behaviours
* Difference is statistically signiﬁcant.
doi:10.1371/journal.pone.0149686.t005
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taking the drug for cognitive or anxiety disorders, suggesting that epilepsy itself may be a risk
factor for abnormal behaviour [41]. Somnolence was reported in about 9% of children in this
review. Other common neurological effects include headache and dizziness. A twofold increase
in the risk of somnolence was observed in children on LEV treatment compared with those
given placebo.
Only two RCTs compared the safety of LEV monotherapy with other AEDs [15, 16]. One
other study compared LEV as monotherapy with placebo for two weeks [17]. For ethical rea-
sons, the participants in this study were allowed to exit the study to receive appropriate treat-
ment when a seizure occurred. Although the study was able to establish the short term efficacy
of LEV monotherapy, very little information on safety was obtained. There is currently no
product license for levetiracetam monotherapy in children less than 16 years old [7]. This is
due to the absence of sufficient safety and efficacy data on monotherapy in this age group.
Aggregated safety data from 17 prospective studies shows that the risks of AEs were lower with
monotherapy treatment than polytherapy. A similar outcome has been reported for AEDs in a
previous study [43]. The effect of AED polytherapy on behaviour is complex. Each drug is
capable of exerting different behavioural effects. This makes causal attribution of such effects
to LEV difficult to establish. Reduction in the number of AEDs or converting to monotherapy
treatment generally leads to behavioural improvement [44].
It was not possible to explore the effect of dose on behaviour, because the doses of LEV in
children with AEs were not specified in several of the articles. Some authors have suggested
that abnormal behaviours in LEV treated patients are idiosyncratic [45]. A previous study
among a large cohort of adults who received LEV during preclinical development did not show
a significant relationship between dose and behaviour problems [41]. Rapid dose titration rate
has however been suggested as a possible risk factor [46].
Table 6. Levetiracetam adverse events leading to treatment discontinuation in prospective and retro-
spective studies.
Adverse event Number of patients
Abnormal behaviour 22
Somnolence 7
Aggravated seizure 6
Aggression 6
Irritability 5
Rash 5
Dizziness 3
Insomnia 3
Fatigue 2
Muscle dystrophy 2
Abdominal pain 1
Abnormal reﬂex 1
Diplopia 1
Headache 1
Loss of appetite 1
Neutropenia 1
Rectal bleeding 1
Speech problem 1
Total 69
doi:10.1371/journal.pone.0149686.t006
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This systematic review has several limitations. The small number of RCTs included in the
meta-analysis reduces the strength of evidence. There were no comparator groups for the pro-
spective cohort studies, hence evidence on comparative safety of LEV was not synthesised from
these studies. The quality of retrospective studies was not assessed due to lack of validated qual-
ity assessment tools; therefore the quality of evidence generated from these retrospective stud-
ies is low. In several of the studies, AEs and not ADRs were reported, therefore the causal
relationship between LEV and AEs are unknown. The poor reporting of drug toxicity in RCTs
of AEDs in children has been noted [47]. In addition, polytherapy RCTs were all add-on stud-
ies, which also made causal attribution difficult. Monotherapy studies in newly diagnosed chil-
dren with epilepsy are necessary to allow comparison of efficacy and toxicity between
individual AEDs [43]. This study is also limited by the lack of information on the reporting
methods in the individual studies, which makes it impossible to determine the effect of report-
ing methods on AE/ADR reporting.
In conclusion, behavioural problems and somnolence were the most prevalent adverse
events to LEV and were the most common cause of treatment discontinuation. Children on
polytherapy have a greater risk of adverse events than those receiving monotherapy. There is
currently insufficient evidence on the safety of LEV in neonates; therefore more studies in this
age group are required.
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